But getting delicate, small RNAs into cells has proved difficult. And the first major RNAi clinical trial -which aimed to treat macular degeneration -was halted in 2009 after reports that the therapy might actually cause blindness. The small RNAs used in the trial, delivered with little modification, triggered cell death through an immune pathway that can be activated by any RNA more than 21 bases long.
RNAi-based therapies fell out of favour after the failed trial, but smaller firms kept working on delivery systems. One such system, developed by Tekmira in Burnaby, Canada, is based on lipid nanoparticles. Patisiran, the drug made by Alnylam to treat a rare disease known as transthyretin-mediated amyloidosis, is an intravenous infusion of small RNAs packaged in these nanoparticles, which resemble a suspension of very small oil droplets. The drug is intended to reduce the production of a mutant liver protein that circulates in the blood and accumulates in other tissues, causing nerve damage and, in many cases, death.
In a 29-patient trial, Alnylam showed that patisiran could reduce blood levels of the protein, transthyretin, by as much as 96%. The company has begun an expanded trial that it plans to conclude in 2017. It is also testing other RNAi-based drugs using its own delivery vehicle, a sugar molecule that is attached to a small RNA and targets a receptor on liver cells.
Another firm, Arrowhead Research of Pasadena, California, has devised a third major delivery system -a customizable polymer that deposits RNAs in target cells. It is now being tested in clinical trials. "We've spent a lot of time in the wilderness trying to solve the delivery problem, " says Christopher Anzalone, Arrowhead's chief executive.
Victor Kotelianski, a former Alnylam executive who directs the RNA centre at the Skolkovo Institute of Science and Technology in Russia, says that caution is warranted. Larger trials of patisiran might uncover side effects that have not yet surfaced, if the RNAi approach is not as precise at hitting its targets as early results suggest. The company has also not yet proved that removing faulty transthyretin proteins from the blood actually resolves patients' symptoms, he says.
There are still enough lingering questions about RNAi's usefulness to give large firms pause. "With a technology like RNAi, you don't necessarily know what its applications in the clinic will be, and those applications might not be compatible or consistent with the goals of the big pharmaceutical companies, " Haussecker says. Before Novartis's decision to abandon most of its RNAi drug development, Merck of New Jersey disclosed on 12 January that it had sold its small-RNA drug-discovery programme to Alnylam for $175 million -much less than the $1.1 billion that Merck paid to kick-start its RNAi research in 2006 (see 'Ups and downs').
Yet Maraganore remains bullish, drawing a parallel between RNAi therapies and monoclonal antibodies -large, complex proteins that bind to specific cell receptors, which were brought to market by focused biotech companies, not big drug firms. "Large companies don't do a good job with technology, " Maraganore says. "It's the same story as with antibodieswe're seeing that movie play out all over again. " ■ BIOTECHNOLOGY
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